全文获取类型
收费全文 | 2716篇 |
免费 | 271篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 171篇 |
妇产科学 | 32篇 |
基础医学 | 351篇 |
口腔科学 | 102篇 |
临床医学 | 268篇 |
内科学 | 509篇 |
皮肤病学 | 115篇 |
神经病学 | 144篇 |
特种医学 | 262篇 |
外科学 | 369篇 |
综合类 | 79篇 |
一般理论 | 7篇 |
预防医学 | 210篇 |
眼科学 | 45篇 |
药学 | 154篇 |
中国医学 | 4篇 |
肿瘤学 | 185篇 |
出版年
2023年 | 20篇 |
2022年 | 18篇 |
2021年 | 29篇 |
2020年 | 24篇 |
2019年 | 18篇 |
2018年 | 55篇 |
2017年 | 55篇 |
2016年 | 56篇 |
2015年 | 89篇 |
2014年 | 109篇 |
2013年 | 155篇 |
2012年 | 95篇 |
2011年 | 97篇 |
2010年 | 111篇 |
2009年 | 117篇 |
2008年 | 73篇 |
2007年 | 98篇 |
2006年 | 102篇 |
2005年 | 87篇 |
2004年 | 80篇 |
2003年 | 58篇 |
2002年 | 55篇 |
2001年 | 40篇 |
2000年 | 36篇 |
1999年 | 53篇 |
1998年 | 109篇 |
1997年 | 103篇 |
1996年 | 110篇 |
1995年 | 76篇 |
1994年 | 88篇 |
1993年 | 51篇 |
1992年 | 47篇 |
1991年 | 49篇 |
1990年 | 31篇 |
1989年 | 52篇 |
1988年 | 43篇 |
1987年 | 54篇 |
1986年 | 47篇 |
1985年 | 42篇 |
1984年 | 24篇 |
1983年 | 23篇 |
1982年 | 31篇 |
1981年 | 23篇 |
1980年 | 27篇 |
1979年 | 23篇 |
1977年 | 24篇 |
1976年 | 24篇 |
1975年 | 25篇 |
1973年 | 19篇 |
1969年 | 19篇 |
排序方式: 共有3019条查询结果,搜索用时 12 毫秒
61.
Amicarelli F; Bucciarelli T; Poma A; Aimola P; Di Ilio C; Ragnelli AM; Miranda M 《Carcinogenesis》1998,19(3):519-523
The effects of methylglyoxal on the growth of a line of human melanoma
cells are investigated. Methylglyoxal inhibits cell growth in a dose-
dependent manner and causes an increase in glyceraldehyde 3-phosphate
dehydrogenase, and glyoxalase 1 and glyoxalase 2 specific activities. The
cellular response to increasing concentrations of methylglyoxal in the
culture medium is also studied by measuring L-lactate production,
reduced-oxidized glutathione levels and apoptotic cell death. Methylglyoxal
seems to promote a change of cell population phenotypic repertoire toward a
more monomorphic phenotype. In conclusion, methylglyoxal seems to induce an
enzymatic cellular response that lowers methylglyoxal levels and selects
the most resistant cells.
相似文献
62.
The hypoxanthine-guanine phosphoribosyl transferase (hprt) locus in 6-
thioguanine (TG) resistant T-lymphocytes is a useful target for the study
of somatic in vivo mutagenesis, since it provides information about a broad
spectrum of mutation. Mutations in the hprt coding region were studied in
124 TG-resistant T-cell clones from 38 healthy, non- smoking male donors
from a previously studied population of bus maintenance workers,
fine-mechanics and laboratory personnel. Their mean age was 43 years (range
23-64) and their hprt mutant frequency was 9.3 +/- 5.2 x 10(-6) (mean +/-
SD, range 1.4-22.6 x 10(-6)). Sequence analysis of hprt cDNA identified 115
unique mutations; 76% were simple base substitutions, 10% were +/-1 bp
frameshifts, and 10% were small deletions within exons (3-52 bp). In
addition, two tandem base substitutions and one complex mutation were
observed. Simple base substitutions were observed at 55 (20%) of 281 sites
known to be mutable in the hprt coding sequence. The distribution of these
mutations was significantly different than would be expected based upon a
Poisson distribution (P < 0.0001), suggesting the existence of
'hotspots'. All of the 87 simple base substitutions occurred at known
mutable sites, but eight were substitutions of a kind that have not
previously been reported at these sites. The most frequently mutated sites
were cDNA positions 197 and 146, with six and five independent mutations
respectively. Four mutations were observed at position 131, and three each
at positions 143, 208, 508 and 617. Transitions (52%) were slightly more
frequent than tranversions (48%), and mutations at GC base pairs (56%) more
common than mutations at AT base pairs (44%). GC > AT was the most
common type of base pair substitution (37%). The majority of the mutations
at GC base pairs (78%) occurred at sites with G in the non-transcribed
strand. All but one of eight mutations at CpG- sites were of the kind
expected from deamination of methylated cytosine. Deletion of a single base
pair (-1 frameshift) was three times more frequent than insertion of a
single bp (+1 frameshift). Almost half (6/13) of the small (3-52 bp)
deletions within the coding sequence clustered in the 5' end of exon 2.
Short repeats and other sequence motifs that have been associated with
replication error were found in the flanking regions of most of the
frameshifts and small deletions. However, several differences in the local
sequence context between +/-1 frameshift and deletion mutations were also
noticed. The present results identify positions 197, 146 and possibly 131
as hotspots for base substitution mutations, and confirm previously
reported hotspots at positions 197, 508 and 617. In addition, the earlier
notion of a deletion hotspot in the 5'end of exon 2 was confirmed. The
observations of these mutational cluster regions in different human
populations suggest that they are due to endogeneous mechanisms of
mutagenesis, or to ubiquitous environmental influences. The emerging
background spectrum of somatic in vivo mutation in the human hprt gene
provides a useful basis for comparisons with radiation or chemically
induced mutational spectra, as well as with gene mutations in human tumors.
相似文献
63.
64.
Phenobarbital and clofibrate, two non-genotoxic carcinogens, have been
investigated regarding the relationship between reactive oxygen species,
antioxidant enzyme expression and apoptosis in primary cultures of rat
hepatocytes. Low toxicity concentrations, 200 and 100 microg/ml for
phenobarbital and clofibrate respectively, were used to examine their
effect on spontaneous or transforming growth factor beta1
(TGFbeta1)-induced apoptosis and on the expression of antioxidant defence
enzymes (superoxide dismutases and catalase). The increased incidence of
apoptotic nuclei was visualized in TGFbeta1-treated cultures with the
fluorescent dye Hoechst 33258 and was quantified under all experimental
conditions by measurement of the hypodiploid peak in DNA histograms
obtained by flow cytometry. Both substances, when added separately to
hepatocyte cultures and incubated for 24 and 48 h, significantly diminished
spontaneous apoptosis and exhibited a slight suppression of
TGFbeta1-induced apoptosis. Endogenous peroxide production by hepatocytes
increased with TGFbeta1, phenobarbital or clofibrate and the increase was
greater with phenobarbital and in the presence of TGFbeta1 with both drugs.
Gene expression of catalase and Mn- and Cu,Zn superoxide dismutases (SOD)
was evaluated by northern blot analysis of hepatocytes incubated in the
presence of phenobarbital or clofibrate with or without TGFbeta1 and the
following differences were detected: phenobarbital induced a significant
decrease in both dismutases (to 56%, P < 0.05, and 55%, P < 0.05, for
Mn- and Cu,Zn-SOD respectively) and a 2-fold increase (P < 0.01) in
catalase; clofibrate induced a slight decrease in both SODs and a 4-fold
increase (P < 0.05) in catalase; TGFbeta1 significantly decreased to 37%
(P < 0.05) expression of catalase while not significantly affecting
expression of both SODs. We conclude that inhibition of spontaneous
apoptosis induced by either phenobarbital or clofibrate is accompanied by
increases in the endogenous levels of peroxides and by significant
induction of catalase gene expression. Furthermore, the lack of effect of
both compounds on TGFbeta1-induced apoptosis could be a consequence of the
inability of these two compounds to counteract the depressing effect of
TGFbeta1 on expression of catalase.
相似文献
65.
66.
67.
Timothy F Cloughesy John Kuhn H Ian Robins Lauren Abrey Patrick Wen Karen Fink Frank S Lieberman Minesh Mehta Susan Chang Alfred Yung Lisa DeAngelis David Schiff Larry Junck Morris Groves Steve Paquette John Wright Kathleen Lamborn Said M Sebti Michael Prados 《Journal of clinical oncology》2005,23(27):6647-6656
PURPOSE: To determine the maximum-tolerated dose (MTD), toxicities, and clinical effect of tipifarnib, a farnesyltransferase (FTase) inhibitor, in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs (EIAEDs). This study compares the pharmacokinetics and pharmacodynamics of tipifarnib at MTD in patients on and off EIAEDs. PATIENTS AND METHODS: Recurrent malignant glioma patients were treated with tipifarnib using an interpatient dose-escalation scheme. Pharmacokinetics and pharmacodynamics were assessed. RESULTS: Twenty-three assessable patients taking EIAEDs received tipifarnib in escalating doses from 300 to 700 mg bid for 21 of 28 days. The dose-limiting toxicity was rash, and the MTD was 600 mg bid. There were significant differences in pharmacokinetic parameters at 300 mg bid between patients on and not on EIAEDs. When patients on EIAEDs and not on EIAEDs were treated at MTD (600 and 300 mg bid, respectively), the area under the plasma concentration-time curve (AUC)(0-12 hours) was approximately two-fold lower in patients on EIAEDs. Farnesyltransferase inhibition was noted at all tipifarnib dose levels, as measured in peripheral-blood mononuclear cells (PBMC). CONCLUSION: Toxicities and pharmacokinetics differ significantly when comparing patients on or off EIAEDs. EIAEDs significantly decreased the maximum concentration, AUC(0-12 hours), and predose trough concentrations of tipifarnib. Even in the presence of EIAEDs, the levels of tipifarnib were still sufficient to potently inhibit FTase activity in patient PBMCs. The relevance of these important findings to clinical activity will be determined in ongoing studies with larger numbers of patients. 相似文献
68.
AM Halefoglu 《Journal of Medical Imaging and Radiation Oncology》2005,49(3):242-245
A pulmonary arteriovenous fistula is an abnormal connection between pulmonary arteries and veins. Patients with Rendu–Osler–Weber syndrome may present with this vascular malformation, which is a typical finding of the disease. Approximately 5–15% of Rendu–Osler–Weber syndrome patients have pulmonary arteriovenous malformations (AVM) and there is usually a family history of AVM in these patients. The malformations are usually located in the lower lobes. In this paper, I describe a 49‐year‐old male patient with dyspnoea, cough, haemoptysis and epistaxis. Physical examination showed nasal telangiectasias, cyanosis of the lips and nails, and a systolic bruit over the left lung. Chest X‐ray revealed a 5‐cm mass in the left lower lobe and after magnetic resonance examination, together with 3‐D magnetic resonance angiography, it was demonstrated to be a pulmonary arteriovenous fistula. The history of a niece with a similiar history of suspected pulmonary arteriovenous fistula led me to consider the possibility of Rendu–Osler–Weber syndrome presenting with a pulmonary arteriovenous fistula. 相似文献
69.
Chun-Wei Lin Laura M. Nocka Brittany L. Stinger Joseph B. DeGrandchamp L. J. Nugent Lew Steven Alvarez Henry T. Phan Yasushi Kondo John Kuriyan Jay T. Groves 《Proceedings of the National Academy of Sciences of the United States of America》2022,119(19)
We reconstitute a phosphotyrosine-mediated protein condensation phase transition of the ∼200 residue cytoplasmic tail of the epidermal growth factor receptor (EGFR) and the adaptor protein, Grb2, on a membrane surface. The phase transition depends on phosphorylation of the EGFR tail, which recruits Grb2, and crosslinking through a Grb2-Grb2 binding interface. The Grb2 Y160 residue plays a structurally critical role in the Grb2-Grb2 interaction, and phosphorylation or mutation of Y160 prevents EGFR:Grb2 condensation. By extending the reconstitution experiment to include the guanine nucleotide exchange factor, SOS, and its substrate Ras, we further find that the condensation state of the EGFR tail controls the ability of SOS, recruited via Grb2, to activate Ras. These results identify an EGFR:Grb2 protein condensation phase transition as a regulator of signal propagation from EGFR to the MAPK pathway.Recently, a class of phenomena known as protein condensation phase transitions has begun to emerge in biology. Originally identified in the context of nuclear organization (1) and gene expression (2), a distinct two-dimensional protein condensation on the cell membrane has now been discovered in the T cell receptor (TCR) signaling system involving the scaffold protein LAT (3–5). TCR activation results in phosphorylation of LAT on at least four distinct tyrosine sites, which subsequently recruit the adaptor protein Grb2 and the signaling molecule PLCγ via selective binding interactions with their SH2 domains. Additional scaffold and signaling molecules, including SOS, GADS, and SLP76, are recruited to Grb2 and PLCγ through further specific protein–protein interactions (6, 7). Multivalency among some of these binding interactions can crosslink LAT molecules in a two-dimensional bond percolation network on the membrane surface. The resulting LAT protein condensate resembles the nephrin:NCK:N-WASP condensate (8) in that both form on the membrane surface under control of tyrosine phosphorylation and exert at least one aspect of functional control over signaling output via a distinct type of kinetic regulatory mechanism (9–11). The basic molecular features controlling the LAT and nephrin protein condensates are common among biological signaling machinery, and other similar condensates continue to be discovered (12, 13). The LAT condensation shares downstream signaling molecules with the EGF-receptor (EGFR) signaling system, raising the question if EGFR may participate in a signaling-mediated protein condensation itself.EGFR signals to the mitogen-activated protein kinase (MAPK) pathway and controls key cellular functions, including growth and proliferation (14–16). EGFR is a paradigmatic model system in studies of signal transduction, and immense, collective scientific effort has revealed the inner workings of its signaling mechanism down to the atomic level (17). EGFR is autoinhibited in its monomeric form. Ligand-driven activation is achieved through formation of an asymmetric receptor dimer in which one kinase activates the other to phosphorylate the nine tyrosine sites in the C-terminal tails (17, 18). There is an obvious conceptual connection between EGFR and the LAT signaling system in T cells. The ∼200-residue–long cytoplasmic tail of EGFR resembles LAT in that both are intrinsically disordered and contain multiple sites of tyrosine phosphorylation that recruit adaptor proteins, including Grb2, upon receptor activation (19). Phosphorylation at tyrosine residues Y1068, Y1086, Y1148, and Y1173 in the EGFR tail creates sites to which Grb2 can bind via its SH2 domain. EGFR-associated Grb2 subsequently recruits SOS, through binding of its SH3 domains to the proline-rich domain of SOS. Once at the membrane, SOS undergoes a multistep autoinhibition-release process and begins to catalyze nucleotide exchange of RasGDP to RasGTP, activating Ras and the MAPK pathway (20).While these most basic elements of the EGFR activation mechanism are widely accepted, larger-scale features of the signaling complex remain enigmatic. A number of studies have reported higher-ordered multimers of EGFR during activation, including early observations by Förster Resonance Energy Transfer and fluorescence lifetime studies (21–23), as have more recent studies using single molecule (24, 25) and computational methods (26). Structural analyses and point mutation studies on EGFR have identified a binding interface enabling EGFR asymmetric dimers to associate (27), but the role of these higher-order assemblies remains unclear. At the same time, many functional properties of the signaling system remain unexplained as well. For example, EGFR is a frequently altered oncogene in human cancers, and drugs (including tyrosine kinase inhibitors) targeting EGFR signaling have produced impressive initial patient responses (28). All too often, however, these drugs fail to offer sustained patient benefits, in large part because of poorly understood resistance mechanisms (29). Physical aspects of the cellular microenvironment have been implicated as possible contributors to resistance development (30), and there is a growing realization that EGFR possesses kinase-independent (e.g., signaling independent) prosurvival functions in cancer cells (31). These points fuel speculation that additional layers of regulation over the EGFR signaling mechanism exist, including at the level of the receptor signaling complex itself.Here we report that EGFR undergoes a protein condensation-phase transition upon activation. We reconstituted the cytoplasmic tails of EGFR on supported bilayers and characterized the system behavior upon interaction with Grb2 and SOS, using total internal reflection fluorescence (TIRF) imaging. This experimental platform has been highly effective for revealing both phase-transition characteristics and functional signaling aspects of LAT protein condensates (4, 5, 10, 32–34). Published reports on the LAT system to date have emphasized SOS (or the SOS proline-rich [PR] domain) as a critical crosslinking element. Titrating the SOS PR domain into an initially homogeneous mixture of phosphorylated LAT and Grb2 revealed a sharp transition to the condensed phase, which we have also observed with the EGFR:Grb2:SOS system. Under slightly different conditions, however, we report observations of an EGFR:Grb2 condensation-phase transition without any SOS or other crosslinking molecule. We show that crosslinking is achieved through a Grb2–Grb2 binding interface. Phosphorylation on Grb2 at Y160 as well as a Y160E mutation [both reported to disrupt Grb2–Grb2 binding (35, 36)] were observed to prevent formation of EGFR condensates. We note that the evidence of Grb2–Grb2 binding we observed occurred in the context of EGFR-associated Grb2, which is localized to the membrane surface; free Grb2 dimers are not necessary.The consequence of EGFR condensation on downstream signaling is characterized by mapping the catalytic efficiency of SOS to activate Ras as a function of the EGFR condensation state. SOS is the primary Ras guanine nucleotide exchange factor (GEF) responsible for activating Ras in the EGFR-to-MAPK signaling pathway (37–40). At the membrane, SOS undergoes a multistep process of autoinhibition release before beginning to activate Ras. Once fully activated, SOS is highly processive, and a single SOS molecule can activate hundreds of Ras molecules before disengaging from the membrane (41–43). Autoinhibition release in SOS is a slow process, which necessitates that SOS be retained at the membrane for an extended time in order for Ras activation to begin (5, 10). This delay between initial recruitment of SOS and subsequent initiation of its Ras GEF activity provides a kinetic proofreading mechanism that essentially requires SOS to achieve multivalent engagement with the membrane (e.g., through multiple Grb2 or other interactions) in order for it to activate any Ras molecules.Experimental results described here reveal that Ras activation by SOS is strongly enhanced by EGFR condensation. Calibrated measurements of both SOS recruitment and Ras activation confirmed enhanced SOS catalytic activity on a per-molecule basis, in addition to enhanced recruitment to the condensates. These results suggest that a Grb2-mediated EGFR protein condensation-phase transition is a functional element controlling signal propagation from EGFR downstream to the MAPK signaling pathway. 相似文献
70.
Carl M. Gay C. Allison Stewart Elizabeth M. Park Lixia Diao Sarah M. Groves Simon Heeke Barzin Y. Nabet Junya Fujimoto Luisa M. Solis Wei Lu Yuanxin Xi Robert J. Cardnell Qi Wang Giulia Fabbri Kasey R. Cargill Natalie I. Vokes Kavya Ramkumar Bingnan Zhang Lauren Averett Byers 《Cancer cell》2021,39(3):346-360.e7